News & Insights

Value, Affordability, and…
Health Policy and Regulation

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Health Technology Assessment…
Cancer

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

Health Technology Assessment…
Measuring and Valuing Outcomes
Cancer

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

EQ-5D and PROMs
Measuring and Valuing Outcomes
Clinical Outcomes

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Health Technology Assessment…
Value, Affordability, and…

Latest Research & Publications

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Uncertainty and Risk in HTA Decision Making

The Distribution of the EQ-5D-5L Index in Patient Populations

Improving Efficiency and Resource Allocation in Future Cancer Care

Four Case Studies to Explore the Added Value of Oxford AHSN

All Publications

OHE Newsroom

Applications open for MSc Fellowship Programme 2025

A switch to vegan diets could save the NHS £6.7 billion per year, new research reveals

Filter results by

EQ-5D and the EuroQol Group: Past, Present and Future

Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK

New Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value

New Member of the EuroQol Group: OHE’s Dr Yan Feng

New Seminar Briefing: Delivering an Outcomes-based NHS: Creating the Right Conditions

Educational Webinar: Multiple Criteria Decision Analysis for Health Care Decision Making – Emerging Good Practices

Vale Kenneth Arrow! Tony Culyer Writes on the Contributions of the Greatest Economist of Our Time and the Intellectual Father of Health Economics

Does a Biomedical Research Centre Affect Patient Care in Local Hospitals?

New OHE Consulting Report: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

OHE is Pleased to Announce the Appointment of Two New Economists: Margherita Neri and Jimena Ferraro

How Should We Choose the Measure of ‘Average’ Preferences?

The Office of Health Economics Becomes a Registered Charity

Subscribe To Our Newsletter

Share on Mastodon